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Understanding of blood coagulation has evolved significantly in recent years. Both new coagulation
proteins and inhibitors have been found and new interactions among previously known compon-
ents of the coagulation system have been discovered. This increased knowledge has led to the
development of various new diagnostic coagulation tests and promising antithrombotic and hae-
mostatic drugs. Several such agents are currently being introduced into clinical medicine for both
the treatment or prophylaxis of thromboembolic disease and for the treatment of bleeding. This
review aims to elucidate these new concepts and to outline some consequences for clinical
anaesthesia and perioperative medicine.
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The coagulation system: new aspects
The coagulation system is considered by many clinicians
to consist just of platelets and clotting factors. For some
time, however, it has been recognized that many more
cellular and molecular components participate in the
coagulation process, thereby forming a multifaceted, well-
balanced system called haemostasis. Moreover, the coagu-
lation system is not only made for forming clots but is also
involved in a variety of defence systems, including tissue
repair, defence against micro-organisms, autoimmune pro-
cesses, arteriosclerosis, tumour growth and metastasis. The
main cellular components of the coagulation systems are
platelets, endothelial cells, monocytes and erythrocytes,
and the main molecular components are the coagulation
factors and inhibitors, fibrinolysis factors and inhibitors,
adhesive proteins (e.g. von Willebrand factor, vWF), inter-
cellular proteins, acute-phase proteins, immunoglobulins,
calcium ions, phospholipids, prostaglandins and certain
cytokines.
Despite this significant diversification, the coagulation
proteins are the core components of the haemostatic system,
forming a complex interplay that is still not entirely under-
stood. Whereas the classic separation of the coagulation path-
way into the extrinsic pathway (initiated by tissue factor) and
intrinsic pathway (initiated by contact activation) still has
certain validity, the newer time-based structuring provides
a much more authentic description of the coagulation pro-
cess.25 This involves the following steps (Fig. 1).
(i) Initiation. Tissue factor (TF) expressed by the damaged
vascular bed binds FVIIa (which circulates in small quant-
ities), which then triggers coagulation by activating FIX to
FIXa and FX to FXa. FXa then binds very rapidly to FII,
producing small amounts of thrombin (FIIa). In a much
slower reaction, FIXa binds to and activates FX to FXa (3
in Fig. 1). Most coagulation processes in vivo are considered
to be initiated by tissue factor, whereas the clinical signi-
ficance of the contact activation (activation of FXII) is still
not yet entirely clear. A recent report, however, has shown
that RNA from disrupted cells may be the long-sought FXII
activator in vivo.72
(ii) Amplification. Because the amount of thrombin gen-
erated at this stage is still too small to activate fibrinogen to
fibrin, there are several feedback amplification mechanisms.
First, generation of FVIIa is increased by activation of FVII
bound to tissue factor by FVIIa, FIXa and FXa. Thrombin
then activates the non-enzymatic cofactors FV and FVIII,
which accelerate the activation of FII by FXa and of FXa
by FIXa, respectively. In a further feedback loop (2 in Fig. 1),
thrombin also activates FXI to FXIa, increasing the genera-
tion of FIXa.
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(iii) Propagation. To maintain continuous thrombin
generation, ensuring the formation of a sufficiently large
clot, large amounts of FXa are produced by the activation
of FX by FIXa and FVIIIa (intrinsic tenase complex). FIXa
stems primarily from the activation of FIX by the FVIIa=
TF–complex.
(iv) Stabilization. Maximum thrombin generation occurs
after the formation of fibrin monomers. Only then is the
amount of thrombin high enough to activate FXIII, a trans-
glutaminase, which then cross-links the soluble fibrin mono-
mers to a stable fibrin meshwork. In addition, thrombin then
activates the thrombin-activatable-fibrinolysis-inhibitor
(TAFI) that protects the clot from fibrinolytic attack.
Surgical procedures often unbalance this elaborate system,
leading to a tendency to either thrombosis or bleeding.
Besides the operative intervention itself and many well-
known clinical risk factors, including immobility, infections,
cancer and drugs, there are various other perioperative factors
that are increasingly being demonstrated to interfere with the
coagulation system, such as hypothermia,56 metabolic acid-
osis,26 volume expanders49 and extracorporeal circulation.8
Such perturbation of coagulation can be assessed by various
laboratory assays. For example, during the first several hours
after surgery there are marked increases in tissue factor, tissue
plasminogen activator, plasminogen activator inhibitor-1
(PAI-1) and vWF, leading to a hypercoagulable and hypo-
fibrinolytic state, as evidenced by increased generation of
coagulationactivationmarkers, suchas thrombin–antithrombin
complexes, fibrinopeptide A and many others.52 57 The levels
of these mediators are known to fluctuate rapidly and their
degree of perturbation is dependent not only on the type,
degree and duration of surgery, but also on the timing of
blood collection.
Perioperative thromboembolism
Who needs thromboprophylaxis?
Surgical patients are at risk of developing venous thrombo-
embolism. It is, however, important to recognize that there
exist both definable operative procedures and definable
groups of patients with significantly higher than normal
rates of postoperative thromboembolism. For instance, it
has been shown that, without prophylaxis, the incidence of
deep vein thrombosis (DVT) is about 14% in gynaecological
surgery, 22% in neurosurgery, 26% in abdominal surgery and
45–60% in orthopaedic surgery. In patients with malignancy
these rates are markedly higher.7 Furthermore, as shown in
Table 1, there are numerous patient-specific risk factors that
also influence the individual risk of thrombosis.
Yet, despite this knowledge and the availability of
effective prophylactic methods and consensus guidelines,
thromboembolism remains an important problem in surgery.
One reason is the low level of implementation of prophylaxis
among many clinicians. In several surveys it has been demon-
strated that there is still considerable under-use of thrombo-
prophylaxis, because of lack of awareness of the problem
of thromboembolism combined with fears of bleeding
complications and scepticism about the cost-effectiveness
of thromboprophylaxis.5 14 Decisions about the need for pro-
phylaxis are, as indicated above, further complicated by the
wide variation in the risk of thromboembolism according to
Fig 1 Current model of coagulation and fibrinolysis. In vivo the coagulation process is initiated mainly by FVIIa bound to tissue factor (TF; large black
arrow), which then activates both FX (1) and FIX (2) (=initiation phase). To increase thrombin generation further, thrombin activates FV, FVIII and FXI in a
feedback-loop (3) (=amplification). Continuation of thrombin generation results mainly from the ongoing generation of FXa by FIXa and FVIIIa
(=propagation). Maximum thrombin generation occurs only after the formation of fibrin, leading to the formation of FXIIIa, which then crosslinks
the fibrin monomers (4) (=stabilization).
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the type of operation and patient-specific risk factors.51 To
overcome this problem, a number of risk assessment models
(RAMs) have been created to assist physicians in making
decisions about whether prophylaxis is needed and which
type is required.20 73 88 An example of an RAM, published
by the American College of Chest Physicians,20 is given in
Table 2. Although RAMs have their limitations, such as the
lack of extensive validation in various surgical settings and
the fact that patients sometimes cannot be categorized, there
are many advantages that outweigh these limitations. The
major advantages of RAMs are: (i) risk stratification is less
likely to be forgotten in the daily routine if each patient has to
be categorized before surgery; (ii) important risk factors are
more often checked if the physician can follow a checklist;
(iii) thromboprophylaxis is less physician-dependent within
departments; and (iv) thromboprophylaxis is less under- or
overused.
Based on our experience, RAMs can be easily imple-
mented in daily routine and, in addition to the above-
mentioned advantages, they produce greater awareness and
more discussion about thromboprophylaxis and a greater
sense of security among anaesthetists and surgeons.
Antithrombotic regimens
Low-molecular weight heparin (LMWH) is the gold standard
in surgical thromboprophylaxis. As has been shown in a
direct comparison of several studies using different prophy-
laxis regimens in hip replacement patients, LMWH, hirudin
and adjusted-dose unfractionated heparin (UFH) led to the
highest risk reduction.20 Whereas hirudin is associated with
an unacceptably high rate of bleeding complications and
adjusted-dose UFH is laborious and requires more than
one injection per day (or an infusion), LMWH has no such
disadvantage and is easy to use as a once-per-day injection
without the necessity of monitoring. It is notable that the
greatest reduction in the risk of thrombosis has been found
in patients with high-risk operations and=or important per-
sonal risk factors.60 61 Although the currently available
LMWHs, including certoparin, dalteparin, enoxaparin,
nadroparin, tinzaparin and reviparin, differ in their pharma-
cokinetic properties, there is no evidence so far that any one of
these products offers more or less protection from throm-
boembolism. In addition, none of the different LMWHs
has been found to be especially useful or disadvantageous
for specific patient groups (e.g. renal or liver insufficiency,
heparin-induced thrombocytopenia) despite the different
pharmacology of the various LMWHs.
There are at least three prophylactic LMWH regimens in
use in patients undergoing high-risk operations (Table 3).33 In
Europe, prophylaxis is traditionally started 12 h before sur-
gery, whereas in North America it is initiated 12–48 h after
surgery. The third regimen starts prophylaxis either more
than 12 h before or 12 h after surgery. LMWH prophylaxis
Table 1 Patient-specific risk factors influencing the perioperative risk of thrombosis
Clinical risk factors Drugs Inherited thrombophilia Acquired thrombophilia
History of thromboembolism Oral contraceptives Activated protein C resistance
(FV Leiden mutation)
Antiphospholipid antibody
syndrome
Malignancy Hormone replacement therapy Prothrombin gene mutation G20210A Sustained elevated FVIII levels
Age >40 yr Antithrombin deficiency
Obesity Protein C deficiency
Varicose veins Protein S deficiency
Prolonged immobilization Hyperhomocysteinaemia
Dehydration
Heart failure
Nephrotic syndrome
Stroke
Myeloproliferative syndrome
Behc¸et’s disease
Pregnancy, puerperium
Table 2 Risk assessment model (RAM) from the American College of Chest Physicians. Adapted from Samama88
Low risk Moderate risk High risk Very high risk
Uncomplicated minor
surgery in patients <40 yr
with no clinical risk factors
Major and minor surgery in
patients 40–60 yr with no
clinical risk factors
Major surgery in patients
>40 yr who have additional
risk factors
Major surgery in patients
>40 yr plus previous venous
thromboembolic or
malignant disease or
hypercoagulable state
Major surgery in patients
<40 yr with no additional
risk factors
Elective major orthopaedic
surgery or hip fracture or
stroke or spinal cord injury
or multiple trauma
Minor surgery in patients
with risk factors
Physiology and management of thromboembolism and haemorrhage
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is started before surgery on the basis of previous observations
that surgical interventions led to activation of coagulation,
probably promoting the generation of thrombi.21 Unfortu-
nately, the optimal regimen is uncertain because direct com-
parisons between these regimens with sufficiently large
sample sizes are not available. A recent analysis of pooled
data from several studies using either pre- or postoperative
prophylaxis, however, has shown that there is no convincing
evidence that starting prophylaxis before surgery is asso-
ciated with a lower incidence of venous thromboembolism
than starting after surgery.100
An increasing body of literature, generally examining hip
replacement patients as a risk model, shows a significant
incidence of DVT developing only weeks after hospital dis-
charge.77 In particular, a recent epidemiological study of
19 586 patients with hip arthroplasty has shown that 76%
of patients suffering from symptomatic thrombosis experi-
enced these events only after hospital discharge (median time
17 days).110 Whereas the overall frequency of symptomatic
thromboses was 2.8%, the rate of venographic thromboses
found in intervention studies is as high as 20%. With regard to
possible complications, such as pulmonary embolism and
post-thrombotic syndrome, asymptomatic thrombosis can
be considered to be clinically significant. However, whether
extended thromboprophylaxis should be given to all patients
routinely after high-risk surgery is still a matter of debate.
Results of several studies using LMWH for 4–6 weeks after
major orthopaedic surgery have shown that the rate of veno-
graphic thromboses can be reduced by more than 50%.77 110
Coumarins, though cheaper, do not seem to offer the same
degree of protection.16 91 Results of a recent systematic
review of all available studies supported the need for
extended out-of-hospital prophylaxis in patients undergoing
arthroplasty surgery.46 It should be noted, however, that the
true benefit of treating asymptomatic, venographic throm-
boses is not yet clear and data about cost-effectiveness are
still lacking.
New antithrombotic drugs
There are many new anticoagulant drugs under investigation
that target novel sites in the coagulation pathway, including
tissue-factor=FVIIa, FVa and FVIIIa, FIXa, FXa, FXIIIa,
PAI-1 and thrombin.108 Only a few of them, however,
have recently entered or will soon enter the market. One
such new anticoagulant is fondaparinux (Arixtra), a
synthetic molecule that is structurally and functionally like
heparin, consisting of five saccharide units (pentasacchar-
ide). Like heparin, it binds and activates antithrombin but
inhibits only FXa and not thrombin.19 Fondaparinux is being
tested extensively in large phase 3 trials in patients under-
going major orthopaedic surgery. These trials have revealed
that fondaparinux 2.5 mg once daily, starting 6 h after surgery,
gives a clear benefit compared with enoxaparin.103 In par-
ticular, the overall incidence of venous thromboembolism up
to day 11 was reduced from 13.7% (371 of 2703 patients) in
the enoxaparin group to 6.8% (182 of 2682 patients) in the
fondaparinux group, with a common odds reduction of 55.2%
in favour of fondaparinux. It should be noted that in some
studies the postoperative interval before starting with the first
dose was considerably different between the enoxaparin and
fondaparinux groups (12–24 vs 6 h). In addition, although the
endpoints of these studies were venographic thromboses,
there was no benefit of fondaparinux over enoxaparin with
regard to the frequency of symptomatic DVT. It will be inter-
esting to see the results of studies using fondaparinux for
other prophylactic indications.
Another new anticoagulant agent is melagatran (Exanta),
a non-covalent, synthetic, direct thrombin inhibitor. Interest-
ingly, it is also available in an oral preparation (ximelagatran)
with very predictable and reproducible pharmacokinetic and
pharmacodynamic profiles.53 Besides oral administration,
melagatran has a number of benefits, including rapid onset
of action, lack of drug–food interactions, and no requirement
for routine blood coagulation monitoring. Both drug forms
have been tested in two large trials as prophylactic treatment
in major orthopaedic surgery.27 29 In one study, melaga-
tran was tested against dalteparin (both drugs given before
surgery followed by ximelagatran), while in the other study
ximelagatran was tested against warfarin (both started after
surgery). The studies concluded that both regimens (subcu-
taneous melagatran followed by oral ximelagatran and oral
ximelagatran alone) were safe, well tolerated and as effective
as the other regimen tested. Although registration of
(xi)melagatran has already been filed in several countries,
some open questions need to be clarified. For instance,
there is at present no drug available to antagonize the effect
of melagatran. Furthermore, the prothrombin time (PT) does
not seem to be an adequate test to measure melagatran activity
(if necessary), as the same melagatran concentration has been
found to be associated with widely varying PT=international
normalized ratio (INR) results depending on the specific
assay used.68
Thromboprophylaxis in patients undergoing regional
anaesthesia
Neuraxial anaesthesia and analgesia provide excellent post-
operative analgesia and allow early mobility after major sur-
gery.9 44 76 84 In addition, there is a considerable group of
patients who wish to stay awake during surgery. Epidural
anaesthesia and analgesia are therefore used frequently in
many centres, although a true outcome benefit in terms
of mortality or major organ dysfunction could not be
confirmed in two recent large-scale prospective randomized
studies, with the exception of reduced pulmonary
complications.76 84
The most feared complication of neuraxial anaesthesia
is epidural haematoma, which has potentially devastating
neurological complications. As more and more patients
are treated with drugs interfering with blood coagulation
or platelet function, the anaesthetist is frequently faced
Physiology and management of thromboembolism and haemorrhage
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with the problem of whether neuraxial anaesthesia is
still an option or whether such co-medication means it is
contraindicated (Table 4). Several US and European societies
have issued guidelines on locoregional anaesthesia in patients
treated with heparin, oral anticoagulation, drugs interfering
with platelet function, and other drugs used for thrombopro-
phylaxis.35 44 89
These guidelines are similar9 35 44 in the following
respects:
Admitting that data are incomplete and, in the case of the
newer antiplatelet and antithrombotic drugs, virtually
non-existent. This applies equally to drug combinations.
Regarding the risk of epidural haematoma during placement
and removal of an epidural catheter to be similar and
therefore applying the same rules.
Considering the risk of peripheral nerve and plexus blocks to
be smaller than the risk of epidural analgesia.
Suggesting the use of low concentrations of local anaesthetics
in combination with opioids (and epinephrine).
Monitoring the patient after surgery to detect paralysis
suggestive of an early epidural haematoma.
Not discussing whether stopping antiplatelet or antico-
agulation therapy is advisable just to allow neuraxial
anaesthesia or analgesia to be instituted, given the fact
that stopping such therapy per se may result in major com-
plications,22 48 89 possibly linked to postoperative hyperco-
agulability.43 90
Reproducing and commenting on these guidelines is
beyond the scope of this review, but the essential aspects
are summarized in Table 5. Many centres have established
local guidelines pending evidence-based national guidelines
(particularly regarding issues not fully covered, such as
drug combinations, including the addition of heparin to
antiplatelet drug therapy).
Management of patients on oral anticoagulants
Perioperative management of patients on regular oral anti-
coagulants is guided by the risk of thromboembolism and the
bleeding associated with different anticoagulant strategies.
While the risk of haemorrhage depends mainly on the site and
type of surgery, the risk of thromboembolism depends on the
indication for regular oral anticoagulation (arterial or venous
prophylaxis), how long ago the patient had a thrombosis,
and on the type of surgery.55 Based on these variables, the
Table 4 Contraindications to neuraxial anaesthesia and analgesia. *As most PT
reagents are very sensitive to FVII deficiency, the INR is often determined by the
FVII level. Therefore, the cut-off level of the INR that constitutes a contraindica-
tion for neuraxial anaesthesia can vary according to whether the course of the INR
is increasing or decreasing. If the INR is increasing, the cut-off level would be
INR>1.5 (FVII levels are mostly about 40%). If the INR is decreasing (e.g. after
ceasing coumarin therapy), the cut-off level would be INR>1.2
Prothrombin time (PT) INR>1.5*
APTT >40 s
Platelet count <50 000 ml1
Table 5 Precautions for neuraxial anaesthesia or analgesia in patients taking anticoagulant drugs. Recommended minimum delay between last dose and placement or
removal of epidural catheter and minimum delay after placement or removal of epidural catheter and subsequent dosing of the drug (modified according to references 33,
38, 105 and 106). The first number represents these authors’ recommendations; recommendations also found in the literature are in parentheses. *With the twice-daily US
dosing regimen, the first dose is usually given 12–24 h after surgery, and removal of the epidural catheter is recommended before initiation of thromboprophylaxis. If the
epidural catheter is left in place during thromboprophylaxis with the twice-daily low molecular weight heparin dose, a 24-h delay between the last heparin dose and
removal of the epidural catheter is recommended.105 **Combination with other drugs influencing the coagulation system including prophylactic heparin may be
dangerous38
Minimum delay between last dose and
placement or removal of epidural catheter
Minimum delay after placement or removal of
epidural catheter and subsequent dosing
Heparin
Unfractionated heparin 4 h (2–4 h) 1 h (0.5–1 h)
Low molecular weight heparin 12 h (10–12 h)* 4 h (2–12 h)
ADP receptor antagonists
Clopidrogel (Plavix) >7 days (7 to >7 days) Immediately
Ticlopidin (Ticlid) (no longer
on the market)
>10 days (10–14 days) Immediately
COX inhibitors
Non-selective, NSAIDs 0 day (0–2 days)** Immediately
COX-2-selective (Rofecoxib,
Vioxx; Celecoxib, Celebrex)
0 day (0 day) Immediately
GPIIb=IIIa antagonists
Abciximab (ReoPro) 2 days (contraindicated) 4 h (2–4 h)
Tirofiban (Aggrastat) 1 day (contraindicated) 4 h (2–4 h)
Eptifibatid (Integrilin) 1 day (contraindicated) 4 h (2–4 h)
Vitamin K antagonists (See Table 4) Immediately
Aspirin (60–325 mg=day) 0 day (0–2 days)** Immediately
Fondaparinux (Arixtra) No epidural catheter recommended
(not recommended to 24 h)
No epidural catheter
recommended
(not recommended to 6 h)
Melagatran, ximelagatran (Exanta) 12 h (8–10 h) 4 h (2–4 h)
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physician needs to determine for each patient the length of the
perioperative anticoagulant-free window and the indication,
type and dose of an alternative anticoagulant given after
discontinuing and before resuming oral anticoagulation.
Principally, in patients at high risk of thromboembolism,
the anticoagulant-free window should be as short as possible,
and during the time from stopping them to resuming couma-
rins an alternative anticoagulant should be given at a thera-
peutic or high prophylactic dose. In this situation, intravenous
UFH is most useful as it can be given up to 2–4 h before
surgery, can be easily monitored, and can be restarted soon
after surgery with slowly increasing doses. LMWHs are less
useful because of their long half-life and the limited possi-
bility of antagonizing their anticoagulant effect. In patients
at low risk of thromboembolism, the oral anticoagulant-free
window can be longer and an alternative anticoagulant, if
necessary at all, can be given in prophylactic doses.54 In
these cases, LMWHs may be preferred. Classification of
patients into groups at high and low risk of thromboembol-
ism, as shown in Table 6, is based mainly on the chronic,
not necessarily perioperative, risk of recurrence, and is thus
somewhat arbitrary.
There is no strict rule as to when coumarins should be
stopped before surgery, as this decision depends on several
factors, including the degree of anticoagulation, the type of
coumarin, the indication, the time between hospital admis-
sion and surgery, and whether UFH can be administered
intravenously. Spontaneous normalization of the INR takes
about 4 days before surgery in patients with an INR between 2
and 3 who are taking warfarin.109 Vitamin K takes at least 24 h
to fully antagonize oral anticoagulation. If urgent reversal of
oral anticoagulation is needed, treatment includes infusion of
fresh frozen plasma (FFP) or prothrombin complex concen-
trate. With both FFP and prothrombin complex concentrate,
elevated INR values can be lowered within minutes. Pro-
thrombin complex concentrate, however, is increasingly
being used because the effect is more reliable and less volume
overload occurs than with FFP.66 A recent report has shown
that recombinant, activated FVIIa (rFVIIa; NovoSeven) can
also lower INR values quickly and effectively.96 This treat-
ment, however, should be considered only if severe bleeding
occurs.
Perioperative haemorrhage
Predictability of bleeding
Some bleeding is due to insufficient or ineffective local
surgical haemostasis and a certain percentage of procedures
are accompanied by a degree of haemorrhage that is deemed
to be excessive. In a large meta-analysis of more than 50
studies of DVT prophylaxis with heparin, it was noted that
among the 7486 controls given placebo, 3.3% were con-
sidered to have bled excessively and that 0.1% died as a
result of haemorrhage.23 Is it possible to identify such
patients before surgery? Even in the 1980s, several studies
had clearly demonstrated that no coagulation test, including
PT, aPTT and bleeding time, is capable of providing this
information.85 102 Newer studies have substantiated these
findings.92 New test systems, such as the platelet function
analyser PFA-100, which tests the adhesion and aggregation
capability of platelets in flowing whole blood, are of limited
value in predicting bleeding. Two recent studies found no
significant correlation between the calculated intra- and
postoperative blood loss and PFA-100 values in patients
undergoing cardiac surgery.28 59 Somewhat better perform-
ance was found for thrombelastography, with a negative
predictive value for postoperative bleeding after cardiac
surgery of >80%, particularly when it was combined with
PFA-100 measurements.15 In particular, the angle alpha was
the best predictor and, in combination with the adenosine
diphosphate PFA test, the predictive accuracy was further
increased, although the positive predictive value was small
(41%). The best method to determine haemorrhagic risk
with surgery is an adequate history and physical examina-
tion. This important message is based on several large trials
Table 6 Recommended management of patients on regular oral anticoagulants
Risk factors Regimen
Low risk No history of thromboembolism. Last venous
thromboembolic episode >3 months. Last arterial
thromboembolic event >1 month. Mechanical
heart valve without previous thromboembolic
event. No permanent patient-specific risk factors
(e.g. cancer, thrombophilia, immobilization etc.)
Preoperative. Stop coumarins 3–5 days before
surgery. If INR<2 start LMWH or UFH at
prophylactic doses until surgery (time between
last heparin injection and surgery depends on dose
and type of heparin)
Postoperative. Give LMWH or UFH starting 12–24 h
after surgery at prophylactic doses until INR>2.
Start coumarins within 24–48 h after surgery
High risk Last venous thromboembolic episode <3 months.
Last arterial thromboembolic event <1 month.
Mechanical heart valve with previous thromboembolic
events. Atrial fibrillation. Permanent patient-specific
risk factors (e.g. cancer, thrombophilia, immobilization
etc.)
Preoperative. Stop coumarins 3–5 days before
surgery. If INR<2 start UFH i.v. at therapeutic doses
until 4–6 h before surgery. Alternatively, LMWH can
be given at therapeutic doses; last injection must be
>24 h before surgery
Postoperative. 8–12 h after surgery start UFH i.v.
(or LMWH s.c.) at increasing doses until therapeutic
level is reached, continue until INR>2.
Start coumarins within 24–48 h after surgery
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showing that patients with a definite or suspicious history of
bleeding are more likely to bleed during surgery than
patients with a negative history.23 45 92 However, the bleed-
ing history may be misleading in patients who have never
been exposed to surgery or trauma, or if the interviewer fails
to ask the appropriate questions.
Nevertheless, preoperative laboratory testing, including
PT, aPTT, platelet count and even larger batteries of tests,
have become routine in most institutions. The physician’s
sense of security and the perceived protection from legal
liability may be the driving forces. As a substantial percent-
age of all unexpected abnormalities detected by preoperative
laboratory tests are ignored, liability would be even greater in
such cases.37 92 Thus, despite the importance of a bleeding
history, the ideal strategy in predicting perioperative haemor-
rhage using coagulation tests remains unknown.
Assessment of the bleeding patient
Surgery or major trauma is the ultimate test of the haemostatic
system. Patients who have never bled to any significant
degree can bleed excessively during surgery. Rapid and
appropriate diagnostics to detect a possible underlying hae-
mostatic defect, either inherited or acquired, are of
pre-eminent importance. A haemostatic defect should always
be considered if bleeding occurs simultaneously at multiple
sites, presents as slow oozing from a non-identifiable source,
or is delayed after initially adequate haemostasis. Bleeding
from a single site or sudden onset of massive bleeding is
probably due to a local structural defect. Assessment of a
patient with a suspected coagulation defect should always
include a thorough re-evaluation of his or her history,
determination of any drugs given before surgery, including
crystalloids, colloids and blood products, and a physical
examination to determine the type and location of the
bleeding. Initial laboratory evaluation should cover the entire
range of possible coagulation defects, including clotting
factor deficiencies, thrombocytopenia (and if possible
thrombocytopathia), hyperfibrinolysis, and disseminated
intravascular coagulation (DIC). Figure 2 gives a brief over-
view of how to proceed if prolongation of either the PT or
aPTT occurs.
Transfusion therapy: evidence and guidelines
Transfusion of blood products is associated with various
risks.1 39 97 Restricted use is therefore advisable39 but
under-transfusion also needs to be avoided.105 Guidelines
have been issued by a variety of societies and expert
panels.1 4 24 95 99 This review focuses on FFP and platelet
transfusions. Guidelines for red blood cell transfu-
sions1 4 24 95 98 99 are beyond the scope of this article.
FFP andplatelet transfusionsare relatively frequently asso-
ciated with side-effects such as febrile, non-haemolytic and
allergic transfusion reactions, bacterial contamination, and
transfusion-relatedacute lunginjury.6 39 69 75 94 Suchproducts
should be restricted to situations in which their efficacy has
been documented. However, there is amazingly little scientif-
ic information available concerning the clinical efficacy of
FFP and platelet transfusions.1 93 The few existing guidelines
consist more of expert opinion than of scientific evidence.
Anaesthetists1 and oncologists93 have issued guidelines for
platelet transfusion. According to these guidelines, prophy-
lactic platelet transfusions are indicated in leukaemia patients
Fig 2 Laboratory evaluation of a prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT). Antiphospholipid antibody (APA)
tests, as mentioned in the aPTT tree, may include lupus anticoagulants, anticardiolipin antibodies and anti-b2-GPI antibodies. Clotting mixing tests are
performed to detect acquired neutralizing antibodies (inhibitors) to single coagulation factors. DD=D-dimers; DIC=disseminated intravascular coagulation;
Fbg=fibrinogen; TT=thrombin time.
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at platelet counts <10 000 ml1 in the absence of fever,
heparin treatment or active minor bleeding (although
lower, safe thresholds have been described by Gmu¨r and
colleagues)34 87 and with platelet counts <20 000 ml1 in
the presence of such risk factors.93 For major surgery, platelet
transfusions are recommended to maintain platelet counts
above 50 000 ml1, particularly if microvascular bleeding
occurs.1 93 Minor surgery, however, can be performed with-
out platelet transfusion in patients with a platelet count
<50 000 ml1.58 In certain situations in which platelet dys-
function may be present, such as after cardiopulmonary
bypass, and when the consequences of bleeding might be
devastating, such as in neurosurgery, maintaining platelet
counts between 50 000 and 100 000 ml1 may be necessary.
Only with severe platelet dysfunction will platelet counts
>100 000 ml1 require transfusion.
Transfusion of FFP is considered to be indicated in the
following situations: urgent reversal of anticoagulation
induced by vitamin K antagonists (besides the use of pro-
thrombin complex concentrates), microvascular bleeding in
the presence of an elevated PT (INR >1.6) or aPTT
(>1.5 times normal) and microvascular bleeding in patients
transfused with >1 blood volume when PT and aPTT are
unavailable.1 81 In contrast, FFP transfusions are contra-
indicated as volume replacement.1 81 Hopefully, the strict
use of such guidelines will decrease the number of inappropri-
ate FFP transfusions.65
Red blood cell transfusions have also been advocated to
improve blood coagulation.82 104 105 It is unlikely, however,
that reduction of the haematocrit alone compromises blood
coagulation significantly. We have shown that decreasing the
haematocrit gradually from 40% to 10%, thereby maintaining
platelet count and coagulation factors at normal levels, does
not compromise blood coagulation in any way, as assessed by
thrombelastography.47
Haemostatic drug therapy
Besides transfusion therapy, treatment of bleeding is often
supplemented with one or more haemostatic drugs. How-
ever, most of these drugs are substitutes for single or com-
bined clotting factors, which do not induce coagulation but
only replenish absent or diminished coagulation factors.
This is important, as coagulation factor concentrates such
as fibrinogen, prothrombin complex concentrate and vWF
concentrate are too often administered in an attempt to
improve coagulation, even though there is no deficiency
of the relevant clotting factor. Although it has long been
known that further elevation of above-normal levels of a
single coagulation factor, e.g. FVIII or FIX, leads to more
effective in vitro coagulation, as evidenced by a shortened
coagulation time,32 58 there is no evidence that this occurs
in vivo or stops bleeding. Apart from the vast experience and
evidence of the efficacy of coagulation factor concentrates
in the treatment of hereditary coagulation factor deficiencies
such as haemophilia, afibrinogenaemia and vWF disease,
there is only sparse evidence of the efficacy of these con-
centrates in patients with surgical bleeding.10 11 13 64 On the
basis of these considerations and the fact that the minimal
concentration of a specific coagulation factor required for
normal haemostasis is known from in vitro experiments, it
seems reasonable to administer coagulation factor concen-
trates only in cases in which a deficiency of the correspond-
ing factor has been demonstrated. To clarify the appropriate
use of coagulation factor concentrates in surgery, however,
randomized trials are needed.
Other widely used haemostatic drugs are antifibrinolytic
agents, including tranexamic acid, aminocaproic acid and
aprotinin, which inhibit the activation of plasminogen and
the activity of plasmin, respectively.107 As shown in several
randomized, placebo-controlled studies, both aprotinin and
tranexamic acid can significantly reduce blood loss in cardiac
surgery when used prophylactically.17 62 71 78 Whether these
results translate into a better overall outcome and justify
routine use in all patients with cardiac surgery, however, is
still debated.
Prophylactic use of antifibrinolytics, mainly aprotinin, in
liver transplantation has also revealed encouraging
results.80 83 The blood-sparing effect of aprotinin was
found to be significant during the post-reperfusion period,
suggesting that inhibition of reperfusion-associated hyper-
fibrinolysis is related to its efficacy. With the currently avail-
able knowledge, aprotinin seems to effectively reduce blood
loss during orthotopic liver transplantation regardless of the
indication.79 In major orthopaedic surgery, mainly joint
replacement surgery, the use of antifibrinolytics has revealed
conflicting results, making their widespread use as routine
medication to reduce blood loss unlikely.3 38 50 106
Apart from their positive effects in prophylaxis, antifi-
brinolytics have shown limited benefits so far in stopping
bleeding episodes. Significant efficacy has been found only
in primary menorrhagia and in gastrointestinal and urogenital
bleeding.67 This may be explained by the fact that mucous
membranes are rich in fibrinolytic substances. In old uncon-
trolled studies, aprotinin was been associated with an
increased rate of thrombotic complications, including myo-
cardial infarction and pulmonary embolism, in patients
undergoing cardiac surgery. Although such adverse effects
have also been reported more recently,36 randomized,
controlled studies have so far failed to demonstrate a signifi-
cant increase in thrombotic complications in patients treated
with aprotinin.17 50
Desmopressin is an analogue of arginine vasopressin and
induces release of vWF from the vascular endothelium,
thereby elevating both vWF and FVIII in the circulation.
Desmopressin has been shown to be effective in treating
bleeding in patients with congenital, mild haemophilia A
and vWF disease type 1.67 To reduce blood loss during
surgery in patients with otherwise normal haemostasis, des-
mopressin proved to be less effective. In a meta-analysis of
17 trials in 1171 patients, investigating desmopressin as
prophylactic treatment in cardiac surgery, desmopressin
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reduced blood loss by only 9%, which was considered not to
be clinically relevant.18 Newer studies have confirmed these
observations, stating that, despite improvement in platelet
function, desmopressin does not seem to have obvious ben-
eficial effects on postoperative haemostasis in patients with-
out any bleeding disorder who are undergoing elective
cardiac surgery.74 Whether a subgroup of patients on pre-
operative aspirin benefit from desmopressin needs to be
investigated further. Moreover, in a comprehensive review
analysing 14 randomized trials of 1034 adult patients sched-
uled for varying non-urgent surgery, the authors found that
there is no convincing evidence that desmopressin mini-
mizes perioperative the allogeneic red blood cell transfusion
requirement in patients who do not have congenital bleeding
disorders. This suggests that there is no benefit in using
desmopressin as a means of minimizing perioperative
allogeneic red blood cell transfusion.41 All in all, it
seems evident that desmopressin primarily provides benefits
in patients with mild congenital haemophilia A or vWF
disease.
rFV11a
Although not yet approved for indications other than bleeding
in haemophiliacs with antibodies, rFVIIa (NovoSeven) may
be the ultimate haemostatic drug. rFVIIa is so far the only
haemostatic drug that not only replaces a missing factor but
actively initiates and promotes the coagulation process. This
is a novel and very promising strategy to treat haemorrhagic
diseases. The haemostatic effect of rFVIIa depends on its
property of binding to TF and activated platelets, thereby
rapidly activating FII to thrombin and FX to FXa respect-
ively.31 70 86 The result is a local thrombin burst that enables
feedbackactivationofintrinsiccoagulationfactors, theactiva-
tion of more platelets, and finally the generation of fibrin.
A major advantage of rFVIIa is that this procoagulant effect
does not occur systemically in the circulation but is limited to
the site where the vessel injury occurred. In about 300 case
reports and small series of patients with severe, life-
threatening bleeding, rFVIIa has proved to be a very potent
haemostatic drug, whatever the cause of the bleeding.2 42 For
instance, rFVIIa has been used successfully in patients with
coumarin-induced bleeding, upper gastrointestinal bleeding,
severe thrombocytopenia and thrombocytopathia and in
patients with severe haemorrhage from trauma, neuro-
surgery, cardiac surgery and obstetric surgery. So far,
there is only one randomized, controlled study of rFVIIa
evaluating its prophylactic effect in patients undergoing
retropubic prostatectomy.30 The study showed that, with one
dose of rFVIIa 40 mg kg1 given during surgery, transfusion
frequency could be reduced from 58% in the placebo group to
0% in the rFVIIa group. Preliminary results from new studies
evaluating the efficacy of rFVIIa in patients undergoing
hepatectomy and patients suffering from severe upper gastro-
intestinal bleeding have similarly shown that blood loss can
be reduced remarkably with rFVIIa.63 However, detailed data
have not yet been published. In addition, large, randomized
studies in patients with severe trauma, liver transplantation
and intracerebral haemorrhage are continuing. They will pro-
vide more information to clarify the uncertainties regarding
its indications, optimal dose regimen, the optimal timing, the
influence of the platelet count, and its cost-effectiveness.
Emerging challenges
A challenging and growing problem in surgery is the
increased use of new, non-antagonizable anticoagulants
such as fondaparinux (Arixtra), (xi)melagatran (Exanta)
and recombinant nematode anticoagulant protein c2
(NAPc2), a FVIIa=TF inhibitor. Although in several non-
clinical reports rFVIIa has been shown to partly reverse
the anticoagulant effect of fondaparinux and NAPc2,12 63 it
remains unclear whether rFVIIa is really effective in clinical
situations and whether it can be used routinely in view of its
high cost. Another non-antagonizable anticoagulant is
recombinant activated protein C (drotrecogin alpha, Xigris)
which is currently approved only in patients with severe
sepsis. Although situations where patients receiving this
drug need surgery may occur only rarely, their management
will be challenging. Bleeding is the most common adverse
reaction associated with Xigris therapy. In the PROWESS
sepsis trial, serious bleeding events were observed in 3.5% of
Xigris-treated and 2.0% of placebo-treated patients during
the 28-day study period.10 Because the risk of bleeding may
be increased significantly in patients with risk factors for
bleeding, the manufacturer recommends that Xigris should
not be used with concurrent heparin therapy, platelet counts
<30 000ml1 and INR>3.0. In cases of bleeding, the infusion
should be stopped immediately. As there is no known antidote
for Xigris and effective antihaemorrhagic strategies are not
known, administration of rFVIIa could theoretically be con-
sidered. However, because Xigris is administered to patients
with sepsis, the often concomitant DIC may limit the use of
rFVIIa.
Summary
Today’s understanding of coagulation is time-based (Fig. 1).
At the site of injury, tissue factor is expressed and binds to
FVIIa, which circulates in minute quantities in its activated
form, activating small quantities of FXa, which produces
small amounts of thrombin (FIIa). By several positive
feedback-loops, the generation of thrombin is amplified
and propagated. When thrombin generation is maximal,
fibrin monomers are formed.
Indications and thromboprophylaxis regimens are
reviewed (Tables 1–3), including the use of recently intro-
duced drugs such as fondaparinux and (xi)melagatran. The
impact of such treatment on patients undergoing regional
anaesthesia (Tables 4 and 5) are outlined. Diagnostic proce-
dures (Fig. 2, Table 6) and treatment regimens for patients
with pre-existing or intraoperative coagulation defects are
increasingly challenging and these are discussed in detail.
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Addendum
A haemostatic (procoagulant) therapy using recombinant fac-
tor VIIa may be beneficial following major trauma. Prelimin-
ary results of a large pivotal phase II multi-centre study in
280 trauma patients have recently been reported (http://www.
novonordisk.com/). Patients treated with recombinant factor
VIIa received less red blood cell transfusions, had fewer
complications and spent less time in intensive care units.
Severe adverse events including thrombo-embolic complica-
tions were equal in both groups.
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